-
1 Comment
iBio, Inc is currently in a long term downtrend where the price is trading 13.0% below its 200 day moving average.
From a valuation standpoint, the stock is 93.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 88.5.
iBio, Inc's total revenue rose by 124.5% to $705K since the same quarter in the previous year.
Its net income has dropped by 116.1% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 160.9% to $-9M since the same quarter in the previous year.
Based on the above factors, iBio, Inc gets an overall score of 2/5.
| Exchange | NYSE MKT |
|---|---|
| CurrencyCode | USD |
| ISIN | US4510332038 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 1.02 |
|---|---|
| PE Ratio | 0.54 |
| Target Price | 4.8 |
| Market Cap | 7M |
| Dividend Yield | None |
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IBIO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
